Literature DB >> 2174203

Effect of delayed captopril therapy on left ventricular mass and myonecrosis during acute coxsackievirus murine myocarditis.

S Rezkalla1, R A Kloner, G Khatib, R Khatib.   

Abstract

The effect of captopril on coxsackievirus B3 murine myocarditis was investigated. Thirty-two, 3-week-old mice were infected with coxsackievirus B3 on day 0 of the study, then randomized into a placebo group or a captopril group starting on day 3 of infection. On day 9 of infection, the mice were put to death. Hearts were weighed and processed for light microscopic examination. Heart weight was 125 +/- 19 mg in the control group versus 102 +/- 14 mg in the captopril group (p less than 0.0003). Amount of necrosis as a percentage of left ventricular section was 3.5% (2.0% to 7.5%) in the placebo group versus 2.0% (0.0% to 5.0%) in the captopril group (p less than 0.01). The amount of dystrophic calcification was 5.0% (0.0% to 27.5%) in the placebo group versus 1.3% (0.0% to 20.0%) in the captopril group (p less than 0.01). The extent of the histopathologic involvement by planimetry was 10.2% in the placebo group versus 5.4% in the captopril group (p = 0.052). We conclude that captopril is beneficial in decreasing left ventricular mass and the amount of myocardial necrosis and calcification in the short term in the murine myocarditis model.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174203     DOI: 10.1016/0002-8703(90)90251-r

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

Review 1.  Diagnosis and management of pediatric myocarditis.

Authors:  Desmond Bohn; Lee Benson
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis.

Authors:  Thomas J Bahk; Melvin D Daniels; Juan S Leon; Kegiang Wang; David M Engman
Journal:  Int J Cardiol       Date:  2007-06-22       Impact factor: 4.164

3.  Therapies to limit myocardial injury in animal models of myocarditis: a systematic review and meta-analysis.

Authors:  Joshua A Silverblatt; Oliver J Ziff; Luke Dancy; Allen Daniel; Ben Carter; Paul Scott; Daniel M Sado; Ajay Shah; Daniel I Bromage
Journal:  Basic Res Cardiol       Date:  2019-10-31       Impact factor: 17.165

Review 4.  SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications.

Authors:  Ossama K Abou Hassan; Calvin C Sheng; Tom Kai Ming Wang; Paul C Cremer
Journal:  Curr Cardiol Rep       Date:  2021-08-03       Impact factor: 2.931

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.